EFFICACY AND SAFETY OF CRIZOTINIB IN ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) RESULTS FROM A PHASE II GLOBAL TRIAL

被引：0
|
作者：
Ferreira, Carlos G. [1 ]
Barrios, C. [2 ]
Shaw, Alice T. [3 ]
Shi, Yuankai [4 ]
De Pas, Tommaso M. [5 ]
Yang, Pan C. [6 ]
Riely, Greg J. [7 ]
Crino, Lucio [8 ]
Iyer, Shrividya [9 ]
Polli, Anna [11 ]
Lanzalone, Silvana [11 ]
Kim, Dong W. [10 ]
机构：
[1] Inst Nacl Canc, Div Clin & Translat Res, Rio De Janeiro, Brazil
[2] Pucrs Sch Med, Dept Med, Porto Alegre, RS, Brazil
[3] Massachusetts Gen Hosp, Dept Thorac Oncol, Boston, MA 02114 USA
[4] Chinese Acad Med Sci Cams, Dept Med Oncol, Beijing, Peoples R China
[5] European Inst Oncol, Med Oncol Unit Resp Tract & Sarcomas, Milan, Italy
[6] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan
[7] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[8] S Maria Della Misericordia Hosp, Perugia, Italy
[9] Pfizer, Oncol, New York, NY USA
[10] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea
[11] Pfizer, Oncol, Milan, Italy
来源：
JOURNAL OF THORACIC ONCOLOGY | 2012年 / 7卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S107 / S108
页数：2
相关论文
共 50 条
  • [21] Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer
    Nishio, Makoto
    Kim, Dong-Wan
    Wu, Yi-Long
    Nakagawa, Kazuhiko
    Solomon, Benjamin J.
    Shaw, Alice T.
    Hashigaki, Satoshi
    Ohki, Emiko
    Usari, Tiziana
    Paolini, Jolanda
    Polli, Anna
    Wilner, Keith D.
    Mok, Tony
    CANCER RESEARCH AND TREATMENT, 2018, 50 (03): : 691 - 700
  • [22] Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer
    Kang, Jin
    Chen, Hua-Jun
    Zhang, Xu-Chao
    Su, Jian
    Zhou, Qing
    Tu, Hai-Yan
    Wang, Zhen
    Wang, Bin-Chao
    Zhong, Wen-Zhao
    Yang, Xue-Ning
    Chen, Zhi-Hong
    Ding, Yan
    Wu, Xue
    Wang, Mei
    Fu, Jian-Gang
    Yang, Zhenfan
    Zhang, Xian
    Shao, Yang W.
    Wu, Yi-Long
    Yang, Jin-Ji
    THORACIC CANCER, 2018, 9 (09) : 1093 - 1103
  • [23] Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.
    Shaw, Alice Tsang
    Peters, Solange
    Mok, Tony
    Gadgeel, Shirish M.
    Ahn, Jin Seok
    Ou, Sai-Hong Ignatius
    Perol, Maurice
    Dziadziuszko, Rafal
    Kim, Dong-Wan
    Rosell, Rafael
    Zeaiter, Ali Hassan
    Liu, Ting
    Golding, Sophie
    Balas, Bogdana
    Noé, Johannes
    Morcos, Peter N.
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (18)
  • [24] Long-term safety of crizotinib in previously treated patients (pts) with ALK-positive advanced/metastatic non-small cell lung cancer (NSCLC)
    Crino, L.
    Ahn, M-J.
    Han, J-Y.
    Liu, X.
    Ou, S-H. I.
    Shaw, A. T.
    Yang, P-C.
    Shi, Y-K.
    Lanzalone, S.
    Polli, A.
    Wilner, K. D.
    Kim, D-W.
    ANNALS OF ONCOLOGY, 2018, 29
  • [25] Crizotinib: A New Treatment Option for ALK-Positive Non-Small Cell Lung Cancer
    O'Bryant, Cindy L.
    Wenger, Sarah D.
    Kim, Miryoung
    Thompson, Lisa A.
    ANNALS OF PHARMACOTHERAPY, 2013, 47 (02) : 189 - 197
  • [26] Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial
    Soo, Ross A.
    Tan, Eng Huat
    Hayashi, Hidetoshi
    Seto, Takashi
    Lin, Chia-Chi
    Ou, Sai-Hong Ignatius
    Kim, Dong-Wan
    Liu, Geoffrey
    Abbattista, Antonello
    Martini, Jean-Francois
    Martini, Francois
    Wong, Chew Hooi
    Toffalorio, Francesca
    Solomon, Benjamin J.
    LUNG CANCER, 2022, 169 : 67 - 76
  • [27] Efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC) and ALK kinase domain mutations
    Shaw, Alice T.
    Martini, Jean-Francois
    Besse, Benjamin
    Bauer, Todd M.
    Lin, Chia-Chi
    Soo, Ross A.
    Riely, Gregory J.
    Ou, Sai-Hong Ignatius
    Clancy, Jill S.
    Li, Sherry
    Thurm, Holger
    Satouchi, Miyako
    Camidge, D. Ross
    Kao, Steven
    Chiari, Rita
    Gadgeel, Shirish
    Felip, Enriqueta
    Solomon, Benjamin J.
    CANCER RESEARCH, 2018, 78 (13)
  • [28] Crizotinib as first line therapy for advanced ALK-positive non-small cell lung cancers
    Chuang, Jody C.
    Neal, Joel W.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2015, 4 (05) : 639 - 641
  • [29] Efficacy and safety of ceritinib in ALK-positive non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LW: Results from the phase II, ASCEND-7 study
    Barlesi, F.
    Kim, D. -W.
    Bertino, E. M.
    van den Bent, M. J.
    Wakelee, H.
    Wen, P. Y.
    Garrido Lopez, P.
    Orlov, S.
    Majem, M.
    McKeage, M.
    Yu, C. -J.
    Hurtado, F. K.
    Arratia, P. Cazorla
    Song, Y.
    Branle, F.
    Shi, M.
    Chow, L. Q.
    ANNALS OF ONCOLOGY, 2019, 30 : 143 - +
  • [30] CLINICAL ACTIVITY OF CRIZOTINIB (PF-02341066), IN ALK-POSITIVE PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)
    Camidge, D. R.
    Bang, Y.
    Iafrate, A. J.
    Kwak, E. L.
    Maki, R. G.
    Solomon, B.
    Ou, S. I.
    Salgia, R.
    Shaw, A.
    Clark, J.
    ANNALS OF ONCOLOGY, 2010, 21 : 123 - 123
12345